SCHEMBL7230408

SCHEMBL7230408

COc1ccc(S(=O)(=O)Nc2cc(C)c(S(=O)(=O)C[N+](=O)[O-])c(C)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.59
FFAR4 Q5NUL3 7/20 0.52
CYP19A1 P11511 1/20 0.52
GABRG2 P18507 1/20 0.51
GABRB3 P28472 1/20 0.51
GABRA3 P34903 1/20 0.51
ALDH1A1 P00352 4/20 0.50
GAA P10253 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 2/20 0.49
POLB P06746 2/20 0.49
CYTH2 Q99418 1/20 0.49
MAPK1 P28482 2/20 0.49
BRD4 O60885 1/20 0.47
KEAP1 Q14145 1/20 0.47
MAPT P10636 1/20 0.46
GFER P55789 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7228550 0.89 FFAR4 (0.53) PKMFFAR4ALDH1A1GAASMN1; SMN2
SCHEMBL7225029 0.87 ALDH1A1 (0.50) PKMFFAR4ALDH1A1GAALMNA
SCHEMBL7231229 0.86 FFAR4 (0.55) PKMFFAR4SMN1; SMN2MAPT
SCHEMBL7221797 0.86 CYTH2 (0.43) PKMALDH1A1GAACYTH2MAPT
SCHEMBL7221678 0.86 CYTH2 (0.56) PKMFFAR4ALDH1A1GAASMN1; SMN2
SCHEMBL7222885 0.85 ALDH1A1 (0.50) PKMFFAR4ALDH1A1GAALMNA
SCHEMBL7223197 0.85 GAA (0.47) ALDH1A1GAASMN1; SMN2POLBCYTH2
SCHEMBL7222407 0.85 FFAR4 (0.49) PKMFFAR4CYP19A1ALDH1A1GAA
SCHEMBL7223946 0.84 CYTH2 (0.46) PKMALDH1A1GAALMNACYTH2
SCHEMBL7230113 0.83 CYTH2 (0.49) PKMFFAR4ALDH1A1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors COLLONGES FRANCOIS (FR) 2003-10-30 US disclosed
US-6509499-B1 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment MERCK PATENTGESELLSCHAFT MIT (DE) 2003-01-21 US disclosed
EP-0946503-B1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GMBH (DE) 2002-03-27 EP disclosed
EP-0946503-A1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GmbH (DE) 1999-10-06 EP disclosed
WO-1998028265-A1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GMBH (DE) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors AKR1B1, ALDOA, AKR1C1 PKM 621/4885FFAR4 2779/4885CYP19A1 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.